Loading
A phase 1/2 trial of REC-4881 run by Recursion Pharmaceuticals Inc., now recruiting.
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) is a phase 1/2 interventional study registered as NCT05552755 by Recursion Pharmaceuticals Inc., with 67 participants planned, started 2023-07-10. Conditions recorded: Familial Adenomatous Polyposis. Interventions recorded: REC-4881 and Placebo.
Shares REC-4881, Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/